Open-label Prospective Clinical Trial Evaluating the Safety and Efficacy of Biosynthetic CLP-PEG-MPC Corneal Implants in Patients Undergoing High-risk Deep Anterior Lamellar Keratoplasty.

• Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) (Other)
• Overall Status: Withdrawn
• CT.gov ID: NCT05667337
• Collaborator: Maisonneuve-Rosemont Hospital (Other)
• Enrollment: 0
• Arms: 2
• Anticipated Duration (Months): 173

Study Details

Study Description

Brief Summary

This is an open-label and prospective clinical trial, in which a maximum of 5 eyes of 5 patients will receive a CLP-PEG-MPC synthetic cornea during deep anterior lamellar keratoplasty (DALK) surgery and will be followed up over 24 months.

Condition or Disease	Intervention/Treatment	Phase
High-risk Corneal Transplantation; Corneal Blindess; Corneal Inflammation; Deep Anterior Lamellar Keratoplasty	Device: CLP-PEG-MPC; Procedure: Human donor cornea penetrating keratoplasty	N/A

Detailed Description

This is a prospective open-label clinical trial of patients who will receive a CLP-PEG-MPC synthetic cornea during deep anterior lamellar keratoplasty (DALK) corneal transplantation surgery and be followed over 24 months. The primary objective is to demonstrate the safety and tolerability of CLP-PEG-MPC biosynthetic corneal implants. The secondary objective is to examine the preliminary efficacy of these implants to stimulate corneal tissue regeneration, provide optical clarity and improvement of vision. Randomization is not appropriate in a first-in-human pilot study. Blinding is not possible as surgeons can easily tell a cell-free implant apart from a donor allograft.

Study Design

• Study Type: Interventional
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Once qualified, subjects will be enrolled to receive a CLP-PEG-MPC implant by DALK. DALK surgery requires the precise dissection of the central 8 mm of the corneal stroma from the underlying posterior corneal layers (Dua layer, Descemet membrane and endothelium, approximately 30 microns thick). The dissection performed during DALK may perforate the posterior corneal layers, requiring conversion to full-thickness penetrating keratoplasty (PKP). Subjects who require conversion to PKP will receive a full-thickness human donor cornea as a safety measure and will be followed per protocol as a comparison group.Once qualified, subjects will be enrolled to receive a CLP-PEG-MPC implant by DALK. DALK surgery requires the precise dissection of the central 8 mm of the corneal stroma from the underlying posterior corneal layers (Dua layer, Descemet membrane and endothelium, approximately 30 microns thick). The dissection performed during DALK may perforate the posterior corneal layers, requiring conversion to full-thickness penetrating keratoplasty (PKP). Subjects who require conversion to PKP will receive a full-thickness human donor cornea as a safety measure and will be followed per protocol as a comparison group.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Étude Clinique Ouverte et Prospective évaluant la sécurité et l'efficacité de la cornée biosynthétique CLP-PEG-MPC Chez Les Patients nécessitant Une kératoplastie Lamellaire antérieure Profonde à Haut Risque.
• Anticipated Study Start Date: Jan 1, 2026
• Anticipated Primary Completion Date: Jan 1, 2040
• Anticipated Study Completion Date: Jun 1, 2040

Arms and Interventions

Arm	Intervention/Treatment
Experimental: CLP-PEG-MPC DALK Subjects having successfully undergone implantation of CLP-PEG-MPC implant using DALK technique	Device: CLP-PEG-MPC; Implantation of a 500 um thick biosynthetic corneal implant utilizing DALK surgical technique
Active Comparator: HDC PKP Subjects having undergone DALK conversion to PKP using a human donor cornea tissue	Procedure: Human donor cornea penetrating keratoplasty; Implantation of a human donor cornea graft utilizing PKP surgical technique

Outcome Measures

Primary Outcome Measures

1. conjunctival inflammation [24 months]

   bulbar conjunctival inflammation (scale 0-none to 4-worse)

2. intraocular inflammation [24 months]

   anterior uveitis (SUN classification of cell and flare for anterior uveitis)

3. complications [24 months]

   occurence of implant-related complications

4. visual acuity - uncorrected [24 months]

   uncorrected visual acuity

5. visual acuity - best-spectacle correction [24 months]

   best-spectacle corrected visual acuity

Secondary Outcome Measures

1. ocular pain [24 months]

   intensity of ocular pain and discomfort (questions 1,3, 10, 11 and 12 from Ocular Surface Disease Index questionnaire)

2. corneal thickness [24 months]

   central corneal pachymetry

3. corneal sensation [24 months]

   Central corneal esthesiometry using Cochet-Bonnet esthesiometer

4. Refraction [24 months]

   eye refractive error

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. adult age (18 years or older at the time of subject eligibility visit)

2. able to provide signed, informed consent

3. unilateral corneal opacity not involving the posterior corneal layers (Descemet membrane and endothelium) for which DALK is indicated

4. visual acuity less than 20/200 in the affected eye and better than 20/50 in the contralateral eye (i.e. monocular blindness)

5. presence of at least one of the following high-risk criteria for corneal transplantation using a human cornea donor graft: 5i) inflammation 5ii) active infection 5iii) stromal neovascularization 5iv) neurotrophism 5v) autoimmune disease 5vi) previous DALK graft failure

6. availability for 24 months of postoperative follow-up

Exclusion Criteria:

1. Age under 18 years

2. Inability to give informed consent

3. Previous corneal perforation precluding DALK surgery

4. Endothelial pathology requiring penetrating keratoplasty

5. Limbal stem cell deficiency affection more than 50% of the limbus

6. Previous penetrating or endothelial keratoplasty

7. Bilateral blindness

8. Nystagmus

9. Uncontrolled glaucoma or intraocular pressure

10. Documented macular disease (age-relate macular degeneration, macula-involving retinal detachment, macular hole)

11. Documented amblyopia of surgical eye

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Centre hospitalier de l'Université de Montréal (CHUM)
• Maisonneuve-Rosemont Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
• ClinicalTrials.gov Identifier: NCT05667337
• Other Study ID Numbers: 20.017
• First Posted: Dec 28, 2022
• Last Update Posted: Dec 28, 2022
• Last Verified: Dec 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM): cornea; biosynthetic implants; tissue regeneration
• Additional relevant MeSH terms: Keratitis; Inflammation

Study Results

No Results Posted as of Dec 28, 2022